Preclinical News and Research

RSS
NovaShunt initiates study to evaluate AFS for refractory ascites patients

NovaShunt initiates study to evaluate AFS for refractory ascites patients

PROMETA Treatment Program rapidly reduces cravings for methamphetamine subjects: Study

PROMETA Treatment Program rapidly reduces cravings for methamphetamine subjects: Study

4SC AG announces the first treatment in Phase I clinical study of 4SC-205

4SC AG announces the first treatment in Phase I clinical study of 4SC-205

ExonHit Therapeutics S.A. selected to participate in the European IMI consortium

ExonHit Therapeutics S.A. selected to participate in the European IMI consortium

Ricerca Biosciences to acquire Discovery and Preclinical business of MDS Pharma Services

Ricerca Biosciences to acquire Discovery and Preclinical business of MDS Pharma Services

Bioactive lipid LPA mediates fibrogenesis in bleomycin mouse model of scleroderma

Bioactive lipid LPA mediates fibrogenesis in bleomycin mouse model of scleroderma

MDS to divest remaining MDS Pharma Services Early Stage business for $45M

MDS to divest remaining MDS Pharma Services Early Stage business for $45M

Positive results from Naurex's Phase I clinical trial of GLYX-13 reported

Positive results from Naurex's Phase I clinical trial of GLYX-13 reported

SafeStitch Medical's AMID Stapler receives European CE Mark

SafeStitch Medical's AMID Stapler receives European CE Mark

Cerus enters into collaborative agreement with EFS for development of INTERCEPT Blood System

Cerus enters into collaborative agreement with EFS for development of INTERCEPT Blood System

Johns Hopkins Hospital initiates Phase I trial with Neogenix's NPC-1C

Johns Hopkins Hospital initiates Phase I trial with Neogenix's NPC-1C

TI commences Phase IIa clinical trial for its lead molecule in CDH

TI commences Phase IIa clinical trial for its lead molecule in CDH

Advaxi to receive fund from CRUK for clinical trial of ADXS11-001

Advaxi to receive fund from CRUK for clinical trial of ADXS11-001

Fourth-quarter and full-year 2009 results announced by Compugen

Fourth-quarter and full-year 2009 results announced by Compugen

Third-quarter fiscal 2010 results announced by Clinical Data

Third-quarter fiscal 2010 results announced by Clinical Data

U.S. PSA screening efficacy lower than in ERSPC-Rotterdam due to lower testing sensitivity

U.S. PSA screening efficacy lower than in ERSPC-Rotterdam due to lower testing sensitivity

Synta Pharmaceuticals' STA-9090 inhibits WT1 protein in AML

Synta Pharmaceuticals' STA-9090 inhibits WT1 protein in AML

NexMed raises $2.3M through private placement

NexMed raises $2.3M through private placement

Phase 1 trial of Cerus' INTERCEPT red blood system meets primary endpoint

Phase 1 trial of Cerus' INTERCEPT red blood system meets primary endpoint

CRT, AstraZeneca announce alliance to develop new anti-cancer drugs

CRT, AstraZeneca announce alliance to develop new anti-cancer drugs

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.